Insulet posts Q4 revenue increase, net loss
By HME News Staff
Updated 10:57 AM CST, Wed February 24, 2021
ACTON, Mass. – Insulet reported revenues of $246.1 million for the fourth quarter of 2020, an increase of 17.5% over the same quarter in 2019. Full-year revenues were $904.4 million, an increase of 22.5% compared to the previous year. For the quarter, U.S. Omnipod revenue was $231.1 million and International Omnipod revenue was $149.2 million. Omnipod revenue for the full year was $834.9 million: $526.9 million in U.S. Omnipod revenue, and $308 million in International Omnipod revenue. The company reported a net loss of $17.1 million for the fourth quarter, and adjusted EBITDA of $35.3 million. Highlights for the company include hitting a milestone of 250,000 customers globally for its Omnipod System and completing the full international commercial launch of its Omnipod DASH. “The fourth quarter marked a strong finish to another successful year for Insulet,” said Shacey Petrovic, president and CEO. “In the face of extraordinary challenges, our team executed our strategy, delivered consistently strong growth, and advanced our key imperatives. We are very proud to celebrate 250,000 customers trusting in Omnipod to simplify their diabetes management and we remain dedicated to our mission to improve the lives of people with diabetes across the globe.”
Comments